<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; animal models</title>
	<atom:link href="http://www.newtbdrugs.org/blog/tag/animal-models/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Fri, 03 Feb 2012 22:43:04 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>TB R&amp;D Weekly Update:  Tailoring TB Treatment Based on Host Genotype?</title>
		<link>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/</link>
		<comments>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 22:40:47 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[Life Cycle of Tuberculosis]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[host-targeting]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[zebra fish]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3466</guid>
		<description><![CDATA[This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2012/02/tb-rd-weekly-update-tailoring-treatment-based-on-host-genotype/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>International TB Research Roadmap Launched!</title>
		<link>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/#comments</comments>
		<pubDate>Thu, 03 Nov 2011 19:52:00 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Announcements]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[stop tb]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3309</guid>
		<description><![CDATA[A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on Saturday at the Union World Conference on Lung Health.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/11/international-tb-research-roadmap-launched/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  ICAAC and TB Drug Clinical Workshop</title>
		<link>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-icaac-and-tb-drug-clinical-workshop/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-icaac-and-tb-drug-clinical-workshop/#comments</comments>
		<pubDate>Thu, 29 Sep 2011 20:14:55 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Events]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[conferences and meetings]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[india]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[online tools]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3225</guid>
		<description><![CDATA[On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19.  Between the two meetings, there were many updates related to TB drug development.  Additional links to TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-icaac-and-tb-drug-clinical-workshop/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  TB Drug Updates in Future Medicinal Chemistry</title>
		<link>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/#comments</comments>
		<pubDate>Thu, 08 Sep 2011 21:23:32 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB News]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[india]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[press]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[tb alliance]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3140</guid>
		<description><![CDATA[Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases.  Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development.  Additional links to TB R&#038;D news are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/09/tb-rd-weekly-update-tb-drug-updates-in-future-medicinal-chemistry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  T-Cell Surface Markers as Potential Biomarkers for TB Treatment</title>
		<link>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-t-cell-surface-markers-as-potential-biomarkers-for-tb-treatment/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-t-cell-surface-markers-as-potential-biomarkers-for-tb-treatment/#comments</comments>
		<pubDate>Tue, 24 May 2011 20:40:35 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2666</guid>
		<description><![CDATA[In this week's article, potential cellular biomarkers are explored in the mouse model with three potential markers: PD-1 and TIM-3 on CD8 T cells and KIRG-1 on both CD4 and CD8 T cells.  The search for validated biomarkers that can predict treatment success has been a difficult one.  The focus of much of the research on biomarkers has been on serum markers, because of practical reasons and considerations of use in resource-limited settings.  Henao-Tamayo, et al., took a different focus looking at markers on the surface of lung T cells.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-t-cell-surface-markers-as-potential-biomarkers-for-tb-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Podcast Interview with Dr. Edward Nardell</title>
		<link>http://www.newtbdrugs.org/blog/2011/05/podcast-interview-with-dr-edward-nardell/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/05/podcast-interview-with-dr-edward-nardell/#comments</comments>
		<pubDate>Tue, 17 May 2011 19:40:27 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2630</guid>
		<description><![CDATA[This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis.  His principal academic appointment is as associate professor of medicine, Harvard Medical School.  In 2002 he joined Partners In Health as Director of Tuberculosis Research. During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/05/podcast-interview-with-dr-edward-nardell/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast interview on TB Drug Tolerance and Efflux Pumps</title>
		<link>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-podcast-interview-on-tb-drug-tolerance-and-efflux-pumps/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-podcast-interview-on-tb-drug-tolerance-and-efflux-pumps/#comments</comments>
		<pubDate>Tue, 03 May 2011 12:00:09 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[drug tolerance]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[targets]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2579</guid>
		<description><![CDATA[The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/05/tb-rd-weekly-update-podcast-interview-on-tb-drug-tolerance-and-efflux-pumps/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Eric Nuermberger</title>
		<link>http://www.newtbdrugs.org/blog/2011/03/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/03/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/#comments</comments>
		<pubDate>Tue, 15 Mar 2011 04:16:11 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[JHU]]></category>
		<category><![CDATA[pk/pd studies]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2302</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled "PA-824 exhibits time-dependent activity in a murine model of tuberculosis" that we covered in a previous TB R&#038;D Weekly Update.  In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and <i>in vitro</i> and preclinical testing of TB drug regimens.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/03/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Podcast Interview with Anne Lenaerts</title>
		<link>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/#comments</comments>
		<pubDate>Tue, 15 Feb 2011 12:00:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2143</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, the WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010.   Dr. Anne Lenaerts is an associate professor at Colorado State University''s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology.  In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Recommended Dose of Pyrazinamide Could Be Inadequate</title>
		<link>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-recommended-dose-of-pyrazinamide-could-be-inadequate/</link>
		<comments>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-recommended-dose-of-pyrazinamide-could-be-inadequate/#comments</comments>
		<pubDate>Tue, 08 Feb 2011 21:17:59 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB Prevention and Control Strategies]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2097</guid>
		<description><![CDATA[In this week's TB R&#038;D update, we look at the whether higher does of pyrazinamide may result in better treatment outcomes for TB patients. The research is published at the end of January online ahead of print in the Antimicrobial Agents and Chemotherapy journal and is entitled "Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis." Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/2011/02/tb-rd-weekly-update-recommended-dose-of-pyrazinamide-could-be-inadequate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

